Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 432

1.

Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis.

Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, Sallman D, Komrokji RS.

Am J Hematol. 2019 Aug 23. doi: 10.1002/ajh.25625. [Epub ahead of print] No abstract available.

PMID:
31444809
2.

Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).

Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L.

Leuk Res. 2019 Sep;84:106194. doi: 10.1016/j.leukres.2019.106194. Epub 2019 Jul 18.

PMID:
31357093
3.

Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks.

Sundaravel S, Kuo WL, Jeong JJ, Choudhary GS, Gordon-Mitchell S, Liu H, Bhagat TD, McGraw KL, Gurbuxani S, List AF, Verma A, Wickrema A.

Clin Cancer Res. 2019 Sep 15;25(18):5638-5649. doi: 10.1158/1078-0432.CCR-19-0924. Epub 2019 Jul 15.

PMID:
31308061
4.

A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).

Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE.

Leuk Res. 2019 Jun;81:56-61. doi: 10.1016/j.leukres.2019.03.008. Epub 2019 Mar 30.

PMID:
31030089
5.

Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis.

Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo WL, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw KL, Bhattacharyya S, Bishop MR, Artz A, Thirman MJ, Moliterno A, Ji P, Levine RL, Godley LA, Steidl U, Bieker JJ, List AF, Saunthararajah Y, He C, Verma A, Wickrema A.

Cancer Discov. 2019 Jun;9(6):778-795. doi: 10.1158/2159-8290.CD-18-1138. Epub 2019 Apr 3.

PMID:
30944118
6.

S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes.

Cheng P, Eksioglu EA, Chen X, Kandell W, Le Trinh T, Cen L, Qi J, Sallman DA, Zhang Y, Tu N, Adams WA, Zhang C, Liu J, Cleveland JL, List AF, Wei S.

Leukemia. 2019 Aug;33(8):2034-2046. doi: 10.1038/s41375-019-0397-9. Epub 2019 Feb 8.

7.

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes.

Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):157-161. doi: 10.1016/j.clml.2018.12.005. Epub 2018 Dec 20.

PMID:
30713125
8.

Non-coding DNA in IBD: from sequence variation in DNA regulatory elements to novel therapeutic potential.

Meddens CA, van der List ACJ, Nieuwenhuis EES, Mokry M.

Gut. 2019 May;68(5):928-941. doi: 10.1136/gutjnl-2018-317516. Epub 2019 Jan 28. Review.

9.

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes.

Sallman DA, List A.

Blood. 2019 Mar 7;133(10):1039-1048. doi: 10.1182/blood-2018-10-844654. Epub 2019 Jan 22. Review.

PMID:
30670444
10.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

11.

Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.

Lee JH, List A, Sallman DA.

Eur J Haematol. 2019 Mar;102(3):203-209. doi: 10.1111/ejh.13207. Epub 2019 Jan 16. Review.

PMID:
30578738
12.

Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.

Betts BC, Locke FL, Sagatys EM, Pidala J, Walton K, Menges M, Reff J, Saha A, Djeu JY, Kiluk JV, Lee MC, Kim J, Kang CW, Tang CH, Frieling J, Lynch CC, List A, Rodriguez PC, Blazar BR, Conejo-Garcia JR, Del Valle JR, Hu CC, Anasetti C.

Front Immunol. 2018 Dec 6;9:2887. doi: 10.3389/fimmu.2018.02887. eCollection 2018.

13.

Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.

Kuykendall AT, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS.

Am J Hematol. 2019 Jan;94(1):87-92. doi: 10.1002/ajh.25335. Epub 2018 Nov 25.

PMID:
30390311
14.

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).

Sekeres MA, Swern AS, Giagounidis A, List AF, Selleslag D, Mittelman M, Schlegelberger B, Göhring G, Li JS, Sugrue MM, Fenaux P.

Blood Cancer J. 2018 Sep 21;8(10):90. doi: 10.1038/s41408-018-0126-z. No abstract available.

15.

SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q.

Talati C, Sallman D, List AF.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):629-635. doi: 10.1016/j.clml.2018.07.293. Epub 2018 Jul 30. Review.

PMID:
30097406
16.

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Sokol L, Wei S, Fridley B, List AF.

Lancet Haematol. 2018 Sep;5(9):e393-e402. doi: 10.1016/S2352-3026(18)30109-1. Epub 2018 Jul 30.

17.

Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML.

Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, Robinson J, Kroeger J, Zhang Q, Zhao YL, Ball M, Komrokji R, List A, Deininger MW, Fridley BL, Santini V, Solary E, Padron E.

Leukemia. 2019 Jan;33(1):205-216. doi: 10.1038/s41375-018-0203-0. Epub 2018 Jul 19.

PMID:
30026572
18.

A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.

List A, Ebert BL, Fenaux P.

Leukemia. 2018 Jul;32(7):1493-1499. doi: 10.1038/s41375-018-0029-9. Epub 2018 Jan 30. Review.

PMID:
29445113
19.

Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR.

Leuk Res. 2018 Apr;67:17-20. doi: 10.1016/j.leukres.2018.01.021. Epub 2018 Jan 31.

20.

Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes.

McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, Sallman D, Zhang X, Song J, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L.

Br J Haematol. 2019 Feb;184(3):450-455. doi: 10.1111/bjh.15099. Epub 2018 Jan 23. No abstract available.

PMID:
29359794
21.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF.

Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.

PMID:
29331635
22.

Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS.

Mei Y, Zhao B, Basiorka AA, Yang J, Cao L, Zhang J, List A, Ji P.

Leukemia. 2018 Apr;32(4):1023-1033. doi: 10.1038/leu.2017.326. Epub 2017 Nov 16.

23.

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.

Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Ann Hematol. 2018 Mar;97(3):435-441. doi: 10.1007/s00277-017-3194-4. Epub 2017 Nov 30.

PMID:
29189896
24.

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.

Sallman DA, Komrokji R, Cluzeau T, Vaupel C, Al Ali NH, Lancet J, Hall J, List A, Padron E, Song J.

Blood Cancer J. 2017 Nov 27;7(12):633. doi: 10.1038/s41408-017-0004-0. No abstract available.

25.

Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report.

Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Fang M, Kopecky KJ, List AF, Pogosov GL, Radich JP, Willman CL, Wood BL, Meshinchi S, Stirewalt DL.

Biopreserv Biobank. 2018 Feb;16(1):42-52. doi: 10.1089/bio.2017.0079. Epub 2017 Nov 27. Erratum in: Biopreserv Biobank. 2018 Apr;16(2):168.

26.

The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.

Duong VH, Padron E, Al Ali NH, Lancet JE, Hall J, Kwok B, Zhang L, Epling-Burnette PK, List AF, Komrokji RS.

Ann Hematol. 2018 Feb;97(2):247-254. doi: 10.1007/s00277-017-3186-4. Epub 2017 Nov 22.

PMID:
29167940
27.

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.

Sébert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Adès L.

Leuk Res. 2017 Dec;63:72-77. doi: 10.1016/j.leukres.2017.10.013. Epub 2017 Oct 27.

PMID:
29112938
28.

A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.

Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):902-907. doi: 10.1016/j.clml.2017.09.007. Epub 2017 Sep 19.

PMID:
29030092
29.

SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.

Sallman DA, Tanaka TN, List A, Bejar R.

Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):613-620. doi: 10.1016/j.clml.2017.09.018. Epub 2017 Sep 25. Review.

PMID:
29025689
30.

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.

Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Maciejewski J, Auberger P, Wei S, Fenaux P, Santini V, List A.

Haematologica. 2017 Dec;102(12):2015-2020. doi: 10.3324/haematol.2016.158857. Epub 2017 Oct 5.

31.

Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.

Talati C, Sallman D, List A.

Semin Hematol. 2017 Jul;54(3):159-166. doi: 10.1053/j.seminhematol.2017.06.003. Epub 2017 Jun 22. Review.

PMID:
28958290
32.

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.

Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e45-e53. doi: 10.1016/j.clml.2017.08.002. Epub 2017 Aug 5.

PMID:
28869184
33.

Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.

Zhang Q, Ball MC, Zhao Y, Balasis M, Letson C, Vedder A, List AF, Epling-Burnette PK, Komrokji RS, Padron E.

Leukemia. 2018 Feb;32(2):532-538. doi: 10.1038/leu.2017.184. Epub 2017 Jun 21.

PMID:
28694526
34.

TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):753-758. doi: 10.1016/j.clml.2017.06.003. Epub 2017 Jun 16.

35.

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF.

J Hematol Oncol. 2017 Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2.

36.

Erythropoietin Receptor Signaling and Lipid Rafts.

McGraw K, List A.

Vitam Horm. 2017;105:79-100. doi: 10.1016/bs.vh.2017.02.002. Epub 2017 Mar 23. Review.

PMID:
28629526
37.

Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.

Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Letson C, Niyongere S, Lu SX, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang W, List AF, Loh ML, Klimek V, Berger MF, Stieglitz E, Padron E, Abdel-Wahab O.

Blood. 2017 Jul 27;130(4):397-407. doi: 10.1182/blood-2017-01-763219. Epub 2017 Jun 2. Erratum in: Blood. 2017 Sep 28;130(13):1602.

38.

New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.

Haider M, Duncavage EJ, Afaneh KF, Bejar R, List AF.

Am Soc Clin Oncol Educ Book. 2017;37:480-494. doi: 10.14694/EDBK_175397.

PMID:
28561687
39.

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP.

J Clin Oncol. 2017 Aug 20;35(24):2745-2753. doi: 10.1200/JCO.2015.66.2510. Epub 2017 May 9.

40.

Pattern classification of EEG signals reveals perceptual and attentional states.

List A, Rosenberg MD, Sherman A, Esterman M.

PLoS One. 2017 Apr 26;12(4):e0176349. doi: 10.1371/journal.pone.0176349. eCollection 2017.

41.

Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.

Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):211-214. doi: 10.1016/j.clml.2016.10.003. Epub 2017 Jan 10.

PMID:
28185797
42.

Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis.

Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E.

Blood. 2017 Mar 30;129(13):1881-1883. doi: 10.1182/blood-2016-12-753210. Epub 2017 Feb 3. No abstract available.

PMID:
28159734
43.

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.

Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R.

Leukemia. 2017 Jun;31(6):1391-1397. doi: 10.1038/leu.2017.33. Epub 2017 Jan 23.

PMID:
28111463
44.

Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858.

Eksioglu EA, Chen X, Heider KH, Rueter B, McGraw KL, Basiorka AA, Wei M, Burnette A, Cheng P, Lancet J, Komrokji R, Djeu J, List A, Wei S.

Leukemia. 2017 Oct;31(10):2172-2180. doi: 10.1038/leu.2017.21. Epub 2017 Jan 18.

45.

Recurrent genetic defects on chromosome 5q in myeloid neoplasms.

Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Cui E, Verma AK, McDevitt MA, List AF, Saunthararajah Y, Sekeres MA, Boultwood J, Ogawa S, Maciejewski JP.

Oncotarget. 2017 Jan 24;8(4):6483-6495. doi: 10.18632/oncotarget.14130.

46.

Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.

Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE.

Am J Hematol. 2017 Mar;92(3):232-237. doi: 10.1002/ajh.24627. Epub 2017 Feb 3.

47.

The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.

Zhang L, McGraw KL, Sallman DA, List AF.

Leuk Lymphoma. 2017 Aug;58(8):1777-1790. doi: 10.1080/10428194.2016.1266625. Epub 2016 Dec 14. Review.

PMID:
27967292
48.

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.

Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E.

Lancet Oncol. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4.

PMID:
27927582
49.

Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).

Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V.

Leuk Res. 2017 Jan;52:50-57. doi: 10.1016/j.leukres.2016.11.008. Epub 2016 Nov 13. Review.

50.

Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.

Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F.

Haematologica. 2016 Nov;101(11):e457-e460. Epub 2016 Jul 14. No abstract available.

Supplemental Content

Support Center